Vaughan & Co Securities’s VanEck Biotech ETF BBH Stock Holding History

Vaughan & Co Securities’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-125	Closed	-$16K	–	55
2020 Q1	$16K	Hold	125	–	–	0.02%	120
2019 Q4	$17.4K	Buy	+125	New	+$16.4K	0.02%	128

Other funds holding BBH

PAG

Pinnacle Advisory Group Columbia, Maryland $2.17B AUM 39.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vaughan & Co Securities's BBH Position: Q2 2020 in Review

Vaughan & Co Securities sold out of VanEck Biotech ETF (BBH) in Q2 2020, closing a stake of 125 shares — an estimated $16K sold.

Vaughan & Co Securities first reported a position in BBH in Q4 2019 and held it in 2 quarters. The position peaked at $17.4K in Q4 2019. 102 funds tracked by Wall St. Rank hold BBH as of Q2 2020.

Vaughan & Co Securities reported no remaining VanEck Biotech ETF position as of Q2 2020 after selling out during the quarter.
Vaughan & Co Securities sold 125 VanEck Biotech ETF shares in Q2 2020, an estimated $16K.
Vaughan & Co Securities first reported a position in VanEck Biotech ETF in Q4 2019 and held it in 2 quarters.
Vaughan & Co Securities's VanEck Biotech ETF position peaked at $17.4K in Q4 2019.
102 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2020.

Based on Vaughan & Co Securities's 13F filing for Q2 2020, filed 10 May 2021.